M2GEN partners with Zephyr AI to identify treatments for cancer patients
Pharmaceutical Technology
FEBRUARY 17, 2023
Oncology-focused bioinformatics firm M2GEN has entered a multi-year strategic collaboration with Zephyr AI to identify treatments and cures for cancer patients. Under the multiyear deal, Zephyr AI will license M2Gen’s RWD and will, in return, provide M2Gen will AI and machine learning technologies to enhance its products and services.
Let's personalize your content